micro-community-banner
 
  • Saved

May 30, 2024
Novel MOA targets age-old condition

Hot flashes—experienced by 70%-80% of menopausal women—are physically distressing and worsen quality of life. Newer therapies, such as NK3R antagonists, leverage a non-hormonal approach to addressing these symptoms.

For example, fezolinetant is a selective NK3R antagonist that directly blocks NKB from binding to the KNDy neuron. NKB is a known trigger of vasomotor symptoms (VMS).

KNDy neurons located at the level of the hypothalamus are inhibited by estrogen and triggered by the neuropeptide NKB, thus resulting in the regulation of body temperature.

During menopause, estrogen decline interferes with this balance involving NKB. Left unopposed, NKB signaling increases KNDy neuronal activity. This process sets off heat-dissipation mechanisms, such as vasodilation and sweating (or VMS).

Thus, fezolinetant helps decrease the frequency and intensity of hot flashes and night sweats, honing in on NK3R with an affinity 450 times higher than that of NK1 or NK2 receptors.

What are your thoughts on this new mechanism of action for the treatment of VMS?

  • May 30, 2024
    major benifit for a lot pf pts that do not desire hormones or pts with breast cancer. biggest problem is the q 3 month LENZ checks
  • May 27, 2024
    non hormone treatment for post menopausal; symptoms is amazing
  • May 27, 2024
    cost
  • May 26, 2024
    Great product, but affordability is a huge problem even doing a PA.
  • May 26, 2024
    I continue to receive good feedback from the patients who could get the Veozah after I prescribed it to them. Please also refer to my response from May 9th 2024
  • May 23, 2024
    Insurance is a huge problem even with PA. Most of my patients cannot afford it. Those that do love it.
  • May 09, 2024
    I have been following the development and now debut of NK3 antagonists for quite some time, I especially like the mechanism of action as it addresses the 'root cause' of the hot flash. I have prescribed Veozah since its availability with excellent feedback from my patients who experience quick onset of therapeutic effect, most do not mind the requirement for Liver Function Tests at commencement and then regularly thereafter. Veozah is an extremely welcome addition to our choice for treatment of VMS. The cost and access problem remains since most PBMs and third party payors require prior authorization and out of pocket co-pay is high even if it is approved/authorized. I believe many more prescriptions would be written if the prior authorization/high copay problems are addressed.
  • April 28, 2024
    It is nice to have another non-hormonal medication options with a new MOA that is available to offer patients who are suffering from VMS
  • April 26, 2024
    It is an intriguing new class. I am always a bit hesitant to use a new class right out of the gate since long term risks are not known.
  • April 26, 2024
    This represents a promising non-hormonal therapeutic approach. This mechanism is distinct from hormone replacement therapy (HRT) and offers a significant advantage for women who are unable or unwilling to use HRT due to contraindications or personal preference. Recent studies and trials have confirmed the efficacy of NK3R antagonists in reducing hot flashes in postmenopausal women, with improvements observed as early as four weeks into treatment.
  • April 25, 2024
    Treatment to improve QOL for VMS
  • April 25, 2024
    Appears to be a safe alternative to hormones in the treatment of VMS with a unique MOA. I’d like to see more efficacy comparison studies vs. estrogen.
  • April 25, 2024
    3 of my patients said they felt better in week one! This is exciting. I have had a few insurance denials.
  • April 25, 2024
    It is a game changer for the management of the VMS lot of women still shy away from the HRT for the management of the VMS for more than one reasonfor the pts who can afford it and have no risk factors for any liver disease it is an excellent choice am sure more drugs focussing on this MOA will come thoough !!!
  • April 25, 2024
    excellent alternative to hormone therapy in women who cant take hormones ,however will insurance pay for it ?
  • April 25, 2024
    It’s very interesting to hear about this new therapy. I was not aware of it. It sounds like it will be cost prohibitive.
  • April 25, 2024
    It is a new option for the treatment of vms symptoms,need close monitoring of liver enzymes, repeat test after 3,6,9 months of treatment.
  • April 25, 2024
    i think it is a great option for those who cannot take estrogen (previous cancer or blood clot risk) however with that comes possibly fragile health already, screening for renal and liver disease, alcohol screening very important as this can increase risks. sometimes antidepressants are still best option for management of sleep, mood depending on the patient.
  • April 25, 2024
    I think that we have to be selective where we use this drug. The drug cost is around $500-$600 a month and we do have to monitor hepatic functions. That being said it certainly seems to work well.
  • April 25, 2024
    Interesting information
    It makes a lot of like an effective treatment
  • April 25, 2024
    I think its a novel treatment non hormonal and those patients who have tried it, have found it successful
Profile Image
  • Saved

May 22, 2024
Dietary Anthocyanin Is Associated With a Lower Prevalence of Hyperuricemia Independently of Metabolic Syndrome Among Females: Results From NHANES 2007-2010 and 2017-2018

Dietary Anthocyanin Is Associated With a Lower Prevalence of Hyperuricemia Independently of Metabolic Syndrome Among Females: Results From NHANES 2007-2010 and 2017-2018

Source : https://pubmed.ncbi.nlm.nih.gov/38742430/

Dietary anthocyanin is associated with a lower prevalence of hyperuricemia independently of MetS among females. Foods rich in anthocyanin should be emphasized for females, especially those aged 40 to 59...

Foods rich in anthocyanin should be emphasized for females, especially those who are menopausal, which may be of potential significance in the prevention of hyperuricemia.

Profile Image
  • Saved

May 22, 2024
Does Everyday Discrimination Account for the Increased Risk of Vasomotor Symptoms in Black Women?: the Study of Women's Health Across the Nation (SWAN)

Does Everyday Discrimination Account for the Increased Risk of Vasomotor Symptoms in Black Women?: the Study of Women's Health Across the Nation (SWAN)

Source : https://pubmed.ncbi.nlm.nih.gov/38595299/

Discrimination is associated with greater concurrent risk of any (but not frequent) VMS, and chronic discrimination is associated with a continuously high reporting of any VMS over time, independent of...

For any vasomotor symptom trajectories, chronic discrimination was associated with "continuously high" and "high pre-FMP-decline post-FMP" versus "FMP-onset low" trajectories.

Profile Image
  • Saved

May 20, 2024
Balance in Transition: Unraveling the Link Between Menopause and Vertigo

Balance in Transition: Unraveling the Link Between Menopause and Vertigo

Source : https://www.cureus.com/articles/248273-balance-in-transition-unraveling-the-link-between-menopause-and-vertigo

The onset of menopause, marked by hormonal fluctuations and a decline in estrogen levels, is suggested to be linked to increased susceptibility to vestibular disturbances. Estrogen, beyond its established association...

Because the vestibular system is influenced by hormonal changes during menopause, this effect could potentially contribute to the emergence of vertigo symptoms during this stage of women’s lives.

Profile Image
  • Saved

May 20, 2024
Influence of Physical Activity Level and Perceived Social Support on Mental Health and Psychological Distress in Women With Menopause Problems

Influence of Physical Activity Level and Perceived Social Support on Mental Health and Psychological Distress in Women With Menopause Problems

Source : https://pubmed.ncbi.nlm.nih.gov/38712645/

Perceived Social Support (PSS) and Physical Activity (PA) could have an important role in reducing psychological distress in women with problems in the menopausal period. The aim was to analyze...

Dependency relationships were found between the prevalence of depression and physical activity level, anxiety and physical activity level, and self-perceived health with physical activity level.

Profile Image